Lineage Cell Therapeutics Q2 Earnings Call Highlights

1 hour ago 1

MarketBeat

Sun, August 9, 2026 astatine 2:04 PM CDT 8 min read

Key Points

Interested successful Lineage Cell Therapeutics, Inc.? Here are 5 stocks we similar better.
Pipeline progress: Lineage precocious preclinical programs successful corneal disease, Type 1 diabetes and proceeding loss, portion Roche and Genentech continued optimizing surgical transportation for the pb OpRegen retinal therapy.
Clinical developments: The OPC1 DOSED survey has treated 2 chronic spinal-cord-injury patients without unexpected information issues, though the survey is not designed to measurement efficacy. OpRegen remains eligible for up to $615 cardinal successful improvement and commercialized milestones positive tiered double-digit royalties.
Financial position: Lineage ended the 4th with $50.8 cardinal successful currency and marketable securities, extending its expected runway into Q3 2028. Revenue fell to $1.1 million, but nett income reached $1.5 million, chiefly owed to a non-cash warrant-liability gain.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) outlined advancement crossed its cell-therapy pipeline during its second-quarter 2026 net call, highlighting preclinical advances successful corneal disease, Type 1 diabetes and proceeding nonaccomplishment programs portion Roche and Genentech proceed surgical-delivery optimization enactment for its pb OpRegen program.

Chief Executive Officer Brian Culley said the company's strategy, which it calls "Lineage 3.0," centers connected utilizing its AlloSCOPE manufacturing level to make allogeneic, oregon off-the-shelf, compartment therapies that tin beryllium produced consistently astatine scale. Culley said the institution aims to people indications wherever tiny archetypal trials could make meaningful attraction signals and wherever Lineage tin clasp improved economics done interior improvement oregon partnerships.

AlloSCOPE Manufacturing Focus

→ No Hangover: Revisiting Microsoft One Week After Earnings

Culley said Lineage has established a two-tier existent bully manufacturing signifier banking and accumulation strategy that it believes tin nutrient millions of vials of a merchandise candidate. Material from those banks has been cleared by the FDA and utilized successful the OpRegen objective trial, helium said.

The institution believes the level tin enactment accumulation costs successful the hundreds of dollars per dose, compared with perchance overmuch higher costs for autologous therapies. Culley emphasized that cell-therapy manufacturing requires reproducibility, purity, potency and scalability, and said changes to a accumulation process aft aboriginal objective trials tin make regulatory and comparability risks.

→ MarketBeat Week successful Review – 08/03 - 08/07

During the question-and-answer session, Culley declined to supply much elaborate accusation connected the vas sizes utilized successful the company's Type 1 diabetes manufacturing work, citing the proprietary quality of the process. He said Lineage's attack is to found a scalable manufacturing process aboriginal alternatively than modify it aboriginal aft objective information are obtained.

Read Entire Article